
Clinical Access
Clinically Accessed Therapy
This therapy is available exclusively to ROEHN Members and requires asynchronous clinical verification through our licensed telehealth network.
Format
Injectable / Sublingual
Frequency
See instructions
Overview
A refined metabolic therapy engineered to regulate appetite, rebalance insulin signaling, and elevate cellular energy. Semaglutide activates GLP-1 pathways to moderate hunger, improve glycemic control, and slow gastric emptying, while methylcobalamin (B12) supports mitochondrial ATP production and sustained daily vitality. This formulation is designed for individuals seeking improved satiety, reduced cravings, enhanced metabolic rhythm, and a calmer, more intuitive relationship with food. Compounded with pharmaceutical-grade precision and aligned with ROEHN’s standard of purity, safety, and clinical-level efficacy.
Mechanism of Action
GLP-1 Receptor Activation (Semaglutide): • Slows gastric emptying • Enhances insulin secretion when needed • Reduces glucagon release • Promotes earlier and longer-lasting satiety • Lowers overall caloric intake naturally Mitochondrial Support (Methylcobalamin B12): • Supports DNA synthesis and neurological function • Enhances ATP production within mitochondria • Helps maintain energy, focus, and metabolic efficiency This dual-pathway approach blends metabolic control with cellular vitality, creating a balanced and sustainable weight-management experience.
Key Benefits
Suggested Use
Administered in micro-dosed weekly intervals based on clinician guidance. Most individuals begin experiencing improved appetite control within 1–2 weeks, with progressive metabolic benefits across 4–8 weeks.
